Silence Therapeutics (NASDAQ:SLN - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect Silence Therapeutics to post earnings of ($0.18) per share and revenue of $3.58 million for the quarter.
Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.42). Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $3.58 million. On average, analysts expect Silence Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Silence Therapeutics Stock Up 6.3%
Silence Therapeutics stock traded up $0.24 during mid-day trading on Tuesday, hitting $4.07. 70,717 shares of the company were exchanged, compared to its average volume of 297,260. The business has a fifty day moving average of $3.37 and a 200 day moving average of $6.31. The company has a market capitalization of $121.85 million, a PE ratio of -2.59 and a beta of 1.20. Silence Therapeutics has a 1-year low of $1.77 and a 1-year high of $24.38.
Analyst Ratings Changes
SLN has been the topic of a number of research reports. Chardan Capital cut their price objective on shares of Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating on the stock in a research report on Friday. The Goldman Sachs Group cut their target price on shares of Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating on the stock in a research report on Friday. Morgan Stanley reduced their target price on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating on the stock in a report on Friday. BMO Capital Markets reduced their price objective on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a research report on Tuesday, March 4th. Finally, HC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Friday, March 7th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Silence Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $33.83.
Get Our Latest Analysis on SLN
Silence Therapeutics Company Profile
(
Get Free Report)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
See Also
Before you consider Silence Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silence Therapeutics wasn't on the list.
While Silence Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
